CFDA and the National Health and Family Planning Commission ("NHFPC") announced the Administrative Measures for the Registration and Record-filing of Pharmaceutical Representatives (for Trial Implementation) (Draft for Comment) ("Draft") on 19 December 2017. It is open for public consultation until 19 January 2018. The draft provides the definition, responsibility, qualification and registration requirements of pharmaceutical representatives. Market Authorisation Holder shall record their employed representatives on the designated platform and seek approval from the medical institutions before conducting any academic promotion activities.